Tumor Mouse Model Confirms MAGE-A3 Cancer Immunotherapeutic As an Efficient Inducer of Long-Lasting Anti-Tumoral Responses

por Gérard, Catherine, Baudson, Nathalie, Ory, Thierry, Louahed, Jamila
Publicado 2014

A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors

por Gérard, Catherine, Baudson, Nathalie, Ory, Thierry, Segal, Lawrence, Louahed, Jamila
Publicado 2015

Expression of tumor-associated antigens in breast cancer subtypes

por Curigliano, Giuseppe, Bagnardi, Vincenzo, Ghioni, Mariacristina, Louahed, Jamila, Brichard, Vincent, Lehmann, Frederic F., Marra, Antonio, Trapani, Dario, Criscitiello, Carmen, Viale, Giuseppe
Publicado 2019

MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells

por Vella, Laura J, Pasam, Anupama, Dimopoulos, Nektaria, Andrews, Miles, Puaux, Anne-Laure, Louahed, Jamila, Knights, Ashley, Chan, Weisan, Woods, Katherine, Cebon, Jonathan
Publicado 2013

Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic

por Baurain, Jean-François, Robert, Caroline, Mortier, Laurent, Neyns, Bart, Grange, Florent, Lebbe, Céleste, Ulloa-Montoya, Fernando, De Sousa Alves, Pedro Miguel, Gillet, Marc, Louahed, Jamila, Jarnjak, Silvija, Lehmann, Frédéric F
Publicado 2018

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a firs...

por Grob, Jean-Jacques, Mortier, Laurent, D’Hondt, Lionel, Grange, Florent, Baurain, Jean Francois, Dréno, Brigitte, Lebbe, Céleste, Robert, Caroline, Dompmartin, Anne, Neyns, Bart, Gillet, Marc, Louahed, Jamila, Jarnjak, Silvija, Lehmann, Frédéric F
Publicado 2017